The News Review:
- ThermaClear Acne Clearing Device from Therative Now Available at …
- Experience Necessary Improving First Impressions Since 1994
- Stiefel Sues Cobrek Perrigo ver Generic Acne Drug
- Stress adds up to more acne
- RediClinic expands health services at HEB
- Will continuous birth control therapy interest acne patients?
- TopoTarget reports Phase II trial results with Avugane¢ in acne …
ThermaClear Acne Clearing Device from Therative Now Available at …
Business Wire (press release)
ThermaClear is the latest addition to ULTA’s prestige collection of advanced skincare solutions. The FDA-cleared clinically proven ThermaClear Acne Clearing Device delivers a controlled 2-second pulse of targeted heat directly to individual pimples attacking acne at its source. Patented Thermal Pulse Technology™ delivers a pulse of heat clearing pimples up to four times faster and often in as little as 24 hours. “We’re thrilled to join ULTA’s growing offering of professional-grade skincare and beauty technologies for use in the comfort of home” said Sandra Lawrence President and CE Therative. “We’re really proud of our ever-growing distribution. Now consumers in more cities than ever across the United States can find ThermaClear and experience the difference.
Experience Necessary Improving First Impressions Since 1994
New York Times
Signature procedure: Treating acne by laser. Acne is very debilitating physically and psychologically. In four treatments I can probably give close to a complete improvement of cystic acne long term. Style statement: Leather pants low-cut clingy black top. Personal odyssey: My mother took me to Israel when I was 15.
Stiefel Sues Cobrek Perrigo ver Generic Acne Drug
IP Law360 (subscription)
has sued Cobrek Pharmaceuticals Inc. and its partner Perrigo Co. over their plans to develop a generic version of the acne treatment Evoclin which Stiefel claims would infringe two of its patents for the topical antibiotic. In a complaint filed Friday in the U. District Court for the District of Delaware Stiefel and its Australian research subsidiary Stiefel Research Australia Pty.
Stress adds up to more acne
Detroit Free Press
Meanwhile Manhattan dermatologist Dr. Cheryl Karcher is performing far fewer liposuctions and Botox injections but is seeing more patients than ever. “They’re all insurance patients for eczema acne and warts — they’re all another hit from the immune system” she says. Karcher explains that the nervous system and hormone systems work together. “They are tightly intertwined and the nervous system is stimulated by stress.
RediClinic expands health services at HEB
Bizjournals.com
The Houston-based health care company plans to offer steroid injections for allergy relief Rocephin antibiotic treatment for common bacterial infections B-12 shots to give patients energy boosts mononucleosis testing and acne treatment. Each RediClinic location is staffed by certified nurse practitioners and physician assistants. RediClinic operates health offices in 15 H-E-B stores in Houston and six in Austin. H-E-B is owned by San Antonio-based.
Will continuous birth control therapy interest acne patients?
Jamaica bserver
Diane 35 has been around for decades and now we have Yasmin. Now very often in dermatology we use Accutane to cure the acne but this drug has very serious side effects and if you get pregnant while you are taking this drug the baby will be damaged. Therefore we very often use the birth control pill with the patient who is using Accutane.
Related from Gxy988: Acupuncture: New therapy helps cancer patients
TopoTarget reports Phase II trial results with Avugane¢ in acne …
PipelineReview.com (press release)
Although the changes in the counts of the acne lesions did not reach statistically significant differences between the three treatment groups (0. 5% 3% and 6%) in this small study the overall assessment both by the investigators and the patients did demonstrate a trend towards more favourable effect in the 3% group. The original protocol had the 6% Avugane™ treatment as the target treatment and it was unfortunate that stability problems prevented a study of this probably optimal concentration. However the short treatment provided to six patients with the 6% Avugane™ did show promising results particularly of the inflammatory lesions. All three grades of the Avugane™ gels were very well tolerated.